Acasti Pharma (CVE:ACST) Stock Price Up 1.8% – Still a Buy?

by · The Cerbat Gem

Acasti Pharma Inc. (CVE:ACST – Get Free Report) shares were up 1.8% during mid-day trading on Thursday . The stock traded as high as C$0.58 and last traded at C$0.58. Approximately 2,450 shares changed hands during trading, a decline of 63% from the average daily volume of 6,576 shares. The stock had previously closed at C$0.57.

Acasti Pharma Stock Performance

The stock’s 50 day moving average is C$0.58 and its two-hundred day moving average is C$0.58. The company has a debt-to-equity ratio of 0.52, a current ratio of 9.74 and a quick ratio of 9.41. The firm has a market cap of C$25.87 million, a P/E ratio of -1.07 and a beta of 1.22.

Acasti Pharma Company Profile

(Get Free Report)

Acasti Pharma Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Featured Stories